Loeuillard Emilien, Bertrand Julien, Herranen Anni, Melchior Chloé, Guérin Charlène, Coëffier Moïse, Aziz Moutaz, Déchelotte Pierre, Savoye Guillaume, Marion-Letellier Rachel
Emilien Loeuillard, Julien Bertrand, Anni Herranen, Chloé Melchior, Charlène Guérin, Moïse Coëffier, Pierre Déchelotte, Guillaume Savoye, Rachel Marion-Letellier, INSERM Unit UMR1073, Rouen University and Rouen University Hospital, Rouen Cedex 76183, France.
World J Gastroenterol. 2014 Dec 28;20(48):18207-15. doi: 10.3748/wjg.v20.i48.18207.
To investigate whether targeting proteasome might reverse intestinal fibrosis in rats.
Chronic colitis was induced in rats by repeated administration of increasing dose of 2,4,6-trinitrobenzene sulfonic acid (TNBS, 15, 30, 45, 60, 60, 60 mg) by rectal injection for 6 wk (from day 0 to day 35), while control rats received the vehicle. TNBS + bortezomib (BTZ) rats received intraperitoneal injections of BTZ twice weekly (from day 37 to day 44) at a dose of 25 mg/kg, whereas the control and TNBS groups received the same amount of the vehicle. Histologic scoring of inflammation and fibrosis was performed. Colonic production of transforming growth factor (TGF)-β was measured by ELISA. Colon fibrosis-related proteins such as phospho-p38, phospho-SMAD2/3, Akt and peroxisome proliferator activated receptor γ (PPARγ) were studied by western blot. Expression of the tight junction proteins, occludin and claudin-1, were assessed by Western blot. Colon proteasome activities (chymotrypsin-like and trypsin-like activities) were assessed.
TNBS-treated rats had a higher colon weight/length ratio compared to control rats (P < 0.01). Furthermore, fibrosis and inflammation scores were higher in TNBS-treated rats compared to control rats (P < 0.01 for both). Colonic production of TGF-β production tended to be higher in TNBS-treated rats (P < 0.06). Fibrosis-related proteins such as phospho-p38, phospho-SMAD2/3, and PPARγ were significantly higher in TNBS-treated rats compared to control rats (all P < 0.05). TNBS rats had a higher expression of Akt compared to control rats (P < 0.01). Tight junction proteins were modified by repeated TNBS challenge: colon occludin expression rose significantly (P < 0.01), whereas claudin-1 expression fell (P < 0.01). Bortezomib inhibition significantly decreased chymotrypsin-like activity (P < 0.05), but had no significant effect on trypsin-like activity (P > 0.05). In contrast, bortezomib had no effect on other studied parameters such as fibrosis score, TGF-β signaling, or tight junction expression (P > 0.05 for all).
Rats with TNBS-induced chronic colitis exhibited colon fibrosis associated with higher TGF-β signaling. Proteasome inhibition by bortezomib had no effect on fibrosis in our experimental conditions.
研究靶向蛋白酶体是否可逆转大鼠肠道纤维化。
通过直肠注射递增剂量的2,4,6-三硝基苯磺酸(TNBS,15、30、45、60、60、60mg),连续6周(从第0天至第35天)诱导大鼠慢性结肠炎,而对照大鼠注射赋形剂。TNBS+硼替佐米(BTZ)组大鼠从第37天至第44天每周两次腹腔注射25mg/kg的BTZ,而对照组和TNBS组注射等量赋形剂。进行炎症和纤维化的组织学评分。通过酶联免疫吸附测定法检测结肠中转化生长因子(TGF)-β的产生。通过蛋白质印迹法研究结肠纤维化相关蛋白,如磷酸化p38、磷酸化SMAD2/3、Akt和过氧化物酶体增殖物激活受体γ(PPARγ)。通过蛋白质印迹法评估紧密连接蛋白occludin和claudin-1的表达。评估结肠蛋白酶体活性(类胰凝乳蛋白酶样和类胰蛋白酶样活性)。
与对照大鼠相比,TNBS处理的大鼠结肠重量/长度比更高(P<0.01)。此外,与对照大鼠相比,TNBS处理的大鼠纤维化和炎症评分更高(两者均P<0.01)。TNBS处理的大鼠结肠中TGF-β的产生倾向于更高(P<0.06)。与对照大鼠相比,TNBS处理的大鼠中磷酸化p38、磷酸化SMAD2/3和PPARγ等纤维化相关蛋白显著更高(均P<0.05)。与对照大鼠相比,TNBS大鼠中Akt的表达更高(P<0.01)。反复TNBS刺激可改变紧密连接蛋白:结肠occludin表达显著升高(P<0.01),而claudin-1表达下降(P<0.01)。硼替佐米抑制显著降低类胰凝乳蛋白酶样活性(P<0.05),但对类胰蛋白酶样活性无显著影响(P>0.05)。相反,硼替佐米对其他研究参数如纤维化评分、TGF-β信号传导或紧密连接表达无影响(均P>0.05)。
TNBS诱导的慢性结肠炎大鼠表现出与更高TGF-β信号传导相关的结肠纤维化。在我们的实验条件下,硼替佐米抑制蛋白酶体对纤维化无影响。